TransCode Therapeutics (RNAZ) Insider Trading & Ownership $9.11 +0.42 (+4.83%) Closing price 04:00 PM EasternExtended Trading$8.70 -0.41 (-4.50%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TransCode Therapeutics (NASDAQ:RNAZ) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage0.10%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$56.55KNumber OfInsiders Selling(Last 3 Years)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RNAZ Insider Buying and Selling by Quarter TransCode Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/28/2023Robert Michael DudleyCEOBuy2$18,849.60$37,699.20 9/28/2023Thomas A FitzgeraldCFOBuy1$18,849.60$18,849.60 6/20/2023Robert Michael DudleyCEOBuy0$94,248.00$0.00 6/9/2023Robert Michael DudleyCEOBuy0$102,009.60$0.00 9/14/2022Robert Michael DudleyCEOBuy0$850,080.00$0.00 (Data available from 1/1/2013 forward) RNAZ Insider Trading Activity - Frequently Asked Questions Who is on TransCode Therapeutics' Insider Roster? The list of insiders at TransCode Therapeutics includes Robert Michael Dudley, and Thomas A Fitzgerald. Learn more on insiders at RNAZ. What percentage of TransCode Therapeutics stock is owned by insiders? 0.10% of TransCode Therapeutics stock is owned by insiders. Learn more on RNAZ's insider holdings. Which TransCode Therapeutics insiders have been buying company stock? The following insiders have purchased RNAZ shares in the last 24 months: Robert Michael Dudley ($37,699.20), and Thomas A Fitzgerald ($18,849.60). How much insider buying is happening at TransCode Therapeutics? Insiders have purchased a total of 3 RNAZ shares in the last 24 months for a total of $56,548.80 bought. TransCode Therapeutics Key ExecutivesMr. Thomas A. Fitzgerald M.B.A. (Age 72)Interim CEO, CFO, President, VP of Administration & Director Compensation: $358.14kDr. Philippe P. Calais Ph.D. (Age 65)Pharm., Pharm.D., Executive Chairman of the Board Compensation: $102.5kDr. Zdravka Medarova Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Dr. Anna Moore Ph.D. (Age 62)Co-Founder, Scientific Advisor & Member of Scientific Advisory Board Ms. Susan Duggan M.B.A.R.N., Senior Vice President of OperationsDr. Daniel R. Vlock M.D. (Age 72)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Coeptis Therapeutics Insider Trading Tempest Therapeutics Insider Trading Cadrenal Therapeutics Insider Trading Cognition Therapeutics Insider Trading ALX Oncology Insider Trading Cara Therapeutics Insider Trading Ovid Therapeutics Insider Trading Cyclo Therapeutics Insider Trading FibroBiologics Insider Trading Generation Bio Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling Hits Market Leaders—Should You Be Worried?3 Small Caps Drawing Insider and Institutional SupportDo They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield Watchlist This page (NASDAQ:RNAZ) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
